Evidence map›Paper›PMID 39962901›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2025

Versatile Features of an Antibody Mimetic Peptide and Its Variants.

Simon Dolles, Simon Leukel, Sabrina Gensberger-Reigl, Anette Rohrhofer, Lena Rauch-Wirth, Kübra Kaygisiz, Christopher V Synatschke, Jan Münch, Barbara Schmidt, Monika Pischetsrieder and 1 more

Abstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Simon DollesDepartment of Chemistry and Pharmacy, Medicinal Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Simon LeukelDepartment of Chemistry and Pharmacy, Medicinal Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Sabrina Gensberger-ReiglDepartment of Chemistry and Pharmacy, Food Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Anette RohrhoferInstitute of Clinical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Lena Rauch-WirthInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Kübra KaygisizMax Planck Institute for Polymer Research, Mainz, Germany.
Christopher V SynatschkeMax Planck Institute for Polymer Research, Mainz, Germany.
Jan MünchInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Barbara SchmidtInstitute of Clinical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Monika PischetsriederDepartment of Chemistry and Pharmacy, Food Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Jutta EichlerDepartment of Chemistry and Pharmacy, Medicinal Chemistry, FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0001-6683-9456

Funding

Deutsche Forschungsgemeinschaft CRC1279Deutsche Forschungsgemeinschaft INST 90/950-1 FUGG
6 · The paper itself

Abstract

Antibody mimetic peptides have evolved as versatile tools for biomedical applications, based on their ability to interfere with protein-protein interactions. We had previously designed a functional mimic of the broadly neutralizing HIV-1 antibody b12 that recognizes the CD4 binding site of the HIV-1 envelope glycoprotein gp120. The molecular details of the interaction of a linear variant of this peptide (H1H3s) with gp120 have now been characterized through cross-linking mass spectrometry, confirming the proposed involvement of the CD4 binding site of gp120 in the interaction. In addition, a variant of the b12 mimetic peptide composed mostly of D-amino acids was shown to be stable towards proteolytic degradation, while the binding and HIV-1 neutralizing properties were largely preserved. Furthermore, a peptide variant in which aspartate residues were replaced with lysine was shown to strongly enhance infection of cells with HIV-1 and GALV glycoprotein pseudotyped viral vectors, respectively, introducing this peptide as a tool to facilitate retroviral gene transfer. Collectively, the presented results highlight the versatile potential therapeutic and gene transfer applications of H1H3s and its variants in particular, as well as antibody mimetic peptides in general.

Indexed as

HIV AntibodiesHIV Envelope Protein gp120PeptidesAntibodies, NeutralizingHIV-1HumansAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Peptidesantibody mimetic peptidesD‐amino acid peptidesgp120HIV‐1infection enhancementmAb b12peptide nanofibrils

Identifiers

PMID39962901
PMCPMC11833279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.